--- title: "XTL Biopharmaceuticals (XTLB) news: delisting and going concern" url: "https://aibio.space/companies/xtl-biopharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "XTLB delisting and going concern news: XTL Biopharmaceuticals regains Nasdaq compliance, faces one-year panel monitor. XTL Biopharmaceuticals Ltd." --- XTLB XTL Biopharmaceuticals Ltd. TASE · Israel # XTL Biopharmaceuticals (XTLB) news XTLB delisting and going concern news Listings · 2026-07-21 ## [XTL Biopharmaceuticals regains Nasdaq compliance, faces one-year panel monitor](https://aibio.space/news/xtl-biopharmaceuticals-regains-nasdaq-compliance-faces-one-year-panel/) Nasdaq staff confirmed on July 20, 2026 that XTL meets four listing rules. Another equity shortfall within the year would lead to a delist determination. ## Latest XTL Biopharmaceuticals news 1. 2026-04-30 Distress [XTL Biopharmaceuticals cannot file its 2025 Form 20-F, citing subsidiary liquidation](https://aibio.space/news/xtl-biopharmaceuticals-cannot-file-2025-form-20-f-citing-subsidiary/) The company says it lacks operational and financial data for its subsidiary The Social Proxy Ltd., which is in liquidation proceedings. 2. 2026-03-20 Listings [XTL Biopharmaceuticals to change ADS ratio to 400 ordinary shares on March 25, 2026](https://aibio.space/news/xtl-biopharmaceuticals-change-ads-ratio-400-ordinary-shares-march-25/) The change has the same effect as a one-for-four reverse ADS split. The ordinary shares are not affected. 3. 2025-04-30 Distress [XTL Biopharmaceuticals 20-F lists going-concern and delisting risks](https://aibio.space/news/xtl-biopharmaceuticals-20-f-lists-going-concern-delisting-risks/) The annual report for 2024 also lists dilution risk and the availability of capital for working capital needs. ## XTL Biopharmaceuticals at a glance - **Ticker**: XTLB - **Listing**: TASE - **Country**: Israel ### Related companies - [PRF Technologies](https://aibio.space/companies/prf-technologies/) NASDAQ: PRFX - [Enlivex](https://aibio.space/companies/enlivex/) NASDAQ: ENLV - [PolyPid](https://aibio.space/companies/polypid/) NASDAQ: PYPD - [Compugen](https://aibio.space/companies/compugen/) NASDAQ: CGEN - [Sol-Gel Technologies](https://aibio.space/companies/sol-gel-technologies/) NASDAQ: SLGL - [Evogene](https://aibio.space/companies/evogene/) NASDAQ: EVGN - [Purple Biotech](https://aibio.space/companies/purple-biotech/) TASE: PPBT - [Silexion Therapeutics](https://aibio.space/companies/silexion-therapeutics/) NASDAQ: SLXN ### Also on TASE - [Psyrex CNS Bio-Tech](https://aibio.space/companies/psyrex-cns-bio-tech/) PSRX - [Purple Biotech](https://aibio.space/companies/purple-biotech/) PPBT - [EPITOMEE MEDICAL LTD](https://aibio.space/companies/epitomee-medical/) EPIT - [NEXTAGE Therapeutics](https://aibio.space/companies/nextage-therapeutics/) NXTG - [NRGENE TECHNOLOGIES LTD](https://aibio.space/companies/nrgene-technologies/) NRGN - [BioLineRX](https://aibio.space/companies/biolinerx/) BLRX ## Questions about XTL Biopharmaceuticals Was XTL Biopharmaceuticals delisted? Our latest story on this, dated Jul 21, 2026: "XTL Biopharmaceuticals regains Nasdaq compliance, faces one-year panel monitor". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/xtl-biopharmaceuticals-regains-nasdaq-compliance-faces-one-year-panel/). Has XTL Biopharmaceuticals issued a going-concern warning? Our latest story on this, dated Apr 30, 2025: "XTL Biopharmaceuticals 20-F lists going-concern and delisting risks". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/xtl-biopharmaceuticals-20-f-lists-going-concern-delisting-risks/). What is the ticker symbol of XTL Biopharmaceuticals? XTL Biopharmaceuticals Ltd. trades under the ticker XTLB on TASE. Where is XTL Biopharmaceuticals listed? XTL Biopharmaceuticals Ltd. is listed on TASE. Our directory also records these other listings: NASDAQ:XTLB. What is the SEC CIK of XTL Biopharmaceuticals? The SEC Central Index Key (CIK) for XTL Biopharmaceuticals Ltd. is 1023549. Its filings are on SEC EDGAR. How many shares does XTL Biopharmaceuticals have outstanding? 946,243,356 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-06-30. Which country or territory is XTL Biopharmaceuticals listed under? Our directory records XTL Biopharmaceuticals Ltd. under Israel. What does XTL Biopharmaceuticals do? Our directory classifies XTL Biopharmaceuticals Ltd. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline. What is the ISIN of XTL Biopharmaceuticals? The ISIN recorded for XTL Biopharmaceuticals Ltd. is IL0010854979. Does aibio.space cover XTL Biopharmaceuticals? aibio.space lists XTL Biopharmaceuticals Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. Where is XTL Biopharmaceuticals incorporated? SEC records list its state or country of incorporation as L3. What is the latest XTL Biopharmaceuticals (XTLB) stock news? Our latest story on XTL Biopharmaceuticals, dated Jul 21, 2026: "XTL Biopharmaceuticals regains Nasdaq compliance, faces one-year panel monitor". Nasdaq staff confirmed on July 20, 2026 that XTL meets four listing rules. Another equity shortfall within the year would lead to a delist determination. [Source](https://aibio.space/news/xtl-biopharmaceuticals-regains-nasdaq-compliance-faces-one-year-panel/). How long will XTL Biopharmaceuticals's cash last? From our story of Jul 21, 2026: It does not address the company's cash, its operating losses or its going-concern status. [Source](https://aibio.space/news/xtl-biopharmaceuticals-regains-nasdaq-compliance-faces-one-year-panel/). Is XTL Biopharmaceuticals a smaller reporting company? SEC records list XTL Biopharmaceuticals Ltd.'s filer category as: Non-accelerated filer. Where is XTL Biopharmaceuticals headquartered? SEC records list its business address as XTL BIOPHARMACEUTICALS LTD, NEW YORK, NY, 10016. ## Investor discussion: XTL Biopharmaceuticals Members talk about XTL Biopharmaceuticals (XTLB). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at XTL Biopharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-07-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1023549/000121390026080006/ea0298779-6k_xtlbio.htm) 2. 2026-05-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1023549/000121390026060565/ea029190401ex99-1.htm) 3. 2026-05-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1023549/000121390026053067/ea0289561-6k_xtlbio.htm) 4. 2026-04-30 Distress Told the SEC a periodic report would be filed late. SEC Form NT 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1023549/000121390026050305/ea0288593-nt20f_xtl.htm) 5. 2026-04-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1023549/000121390026048875/ea028812601ex99-1.htm) 6. 2026-03-20 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1023549/000121390026032348/ea028269501ex99-1.htm) 7. 2026-02-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1023549/000121390026021691/ea027904501ex99-1.htm) 8. 2026-01-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1023549/000121390026008572/ea0274345-6k_xtlbio.htm) 9. 2026-01-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1023549/000121390026007213/ea027375301ex99-1_xtlbio.htm) 10. 2026-01-13 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1023549/000121390026003672/ea0272612-6k_xtlbio.htm) 11. 2025-12-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1023549/000121390025126039/ea027112701ex99-1_xtlbio.htm) 12. 2025-04-30 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1023549/000121390025037590/ea0239661-20f_xtlbio.htm) 13. 2025-02-03 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1023549/000121390025009420/ea0229687-6k_xtlbio.htm) 14. 2024-12-30 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1023549/000121390024113540/ea022610401-6k_xtlbio.htm) 15. 2024-11-12 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1023549/000121390024096334/ea0220818-6k_xtlbio.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open TASE:XTLB on TradingView](https://www.tradingview.com/symbols/TASE-XTLB/). ## SEC filings and registration - **SEC name**: Xtl Biopharmaceuticals Ltd - **CIK**: 1023549 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: XTLB (Nasdaq) - **State or country of incorporation**: L3 - **Filer category**: Non-accelerated filer - **Business address**: XTL BIOPHARMACEUTICALS LTD, NEW YORK, NY, 10016 - **Phone**: 972 9 955 7080 - **Shares outstanding**: 946,243,356 as of 2025-12-31 (20-F filed 2026-06-30) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1023549/000121390026109415/ea0308492-6k_xtlbio.htm) filed 2026-10-14 - [6-K](https://www.sec.gov/Archives/edgar/data/1023549/000121390026085693/ea0300815-6k_xtlbiophar.htm) filed 2026-08-05 - [6-K](https://www.sec.gov/Archives/edgar/data/1023549/000121390026080006/ea0298779-6k_xtlbio.htm) filed 2026-07-21 - [20-F](https://www.sec.gov/Archives/edgar/data/1023549/000121390026073831/ea0296095-20f_xtlbio.htm) filed 2026-06-30 - [6-K](https://www.sec.gov/Archives/edgar/data/1023549/000121390026073813/ea0296604-6k_xtlbio.htm) filed 2026-06-30 - [6-K](https://www.sec.gov/Archives/edgar/data/1023549/000121390026073158/ea0296376-6k_xtlbio.htm) filed 2026-06-29 - [6-K](https://www.sec.gov/Archives/edgar/data/1023549/000121390026070771/ea0295469-6k_xtlbio.htm) filed 2026-06-23 - [6-K](https://www.sec.gov/Archives/edgar/data/1023549/000121390026060565/ea0291904-6k_xtlbio.htm) filed 2026-05-22 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001023549), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details XTL Biopharmaceuticals Ltd. is a public biotech or pharmaceutical company listed on TASE under the ticker XTLB, recorded under Israel. The directory classifies it as Biopharma / pharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: XTL Biopharmaceuticals Ltd. - **Ticker**: XTLB - **Listing**: TASE - **Country or territory**: Israel - **Business scope**: Biopharma / pharmaceuticals - **ISIN**: IL0010854979 - **Other listed symbols**: NASDAQ:XTLB - **Last quote in directory**: 2026-10-22 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/TASE-XTLB/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/xtl-biopharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "XTL Biopharmaceuticals (XTLB) news: delisting and going concern", 2026-10-31, https://aibio.space/companies/xtl-biopharmaceuticals/